Introduction to AXIN2-Related Phenotypic Expansion

Recent breakthroughs in genomic medicine have dramatically altered our understanding of the AXIN2 gene, historically associated with oligodontia-colorectal cancer syndrome (ODCRCS). However, a seminal study published in 2026 has introduced the concept of AXIN2-related phenotypic expansion, identifying a much broader range of clinical manifestations. Researchers identified five individuals harboring de novo, heterozygous variants—specifically p.(Glu66Lys), p.(Glu66Gly), and p.(Gly67Arg)—located within the critical tankyrase-binding domain of the protein. Unlike the classic presentation, these patients exhibited a complex syndrome involving global developmental delay, microcephaly, and ectodermal dysplasia. Furthermore, these findings suggest that the clinical impact of AXIN2 variants is significantly more diverse than previously documented in medical literature. Consequently, clinicians must now consider AXIN2 as a candidate gene for patients presenting with multiple congenital anomalies. This expansion not only challenges existing diagnostic frameworks but also emphasizes the importance of precision animal modeling in resolving the pathogenicity of de novo variants. By integrating human clinical data with advanced biological models, the medical community can better navigate the complexities of Wnt signaling disorders and their systemic effects.

The Classic Phenotype vs. New Clinical Observations

Historically, pathogenic variants in the AXIN2 gene were primarily linked to autosomal dominant oligodontia and a predisposition to early-onset colorectal cancer. This classic phenotype, known as ODCRCS, focused largely on dental agenesis and gastrointestinal polyposis. Nevertheless, the recent identification of de novo variants in the tankyrase-binding domain has revealed a striking AXIN2-related phenotypic expansion. In addition to dental issues, affected individuals presented with severe neurodevelopmental delays and structural microcephaly. Moreover, the study documented a wide array of systemic involvement, including limb defects, ophthalmologic abnormalities, and genitourinary malformations. These findings indicate that specific mutations in the early protein domains of AXIN2 may disrupt embryonic development more profoundly than the truncating mutations typically seen in ODCRCS. Because these symptoms overlap with other genetic syndromes, the discovery underscores the need for high-throughput sequencing in pediatric diagnostics. Subsequently, these clinical observations suggest that AXIN2 plays a more vital role in early morphogenesis than once thought. Therefore, understanding the site-specific impact of variants is essential for accurate prognosis and management of these complex patients.

AXIN2-Related Phenotypic Expansion in the Tankyrase Domain

The molecular mechanism driving this phenotypic expansion centers on the tankyrase-binding domain (TBD) of the AXIN2 protein. Under normal physiological conditions, AXIN2 acts as a negative regulator of the Wnt signaling pathway by scaffolding the β-catenin destruction complex. The TBD is crucial because it facilitates binding with tankyrase, an enzyme that regulates AXIN2 levels through a post-translational modification called PARsylation. Structural modeling performed in the study suggests that variants like p.Glu66Lys disrupt this binding interface. When AXIN2 cannot bind to tankyrase, its internal stability and degradation cycles are severely compromised. Consequently, this leads to dysregulated Wnt signaling, which is a fundamental pathway for cell fate determination and organogenesis. Furthermore, the researchers observed that these specific mutations do not simply cause a loss of function. Instead, they may exert gain-of-function or dominant negative effects depending on the cellular environment. This context-dependent activity explains why these individuals present with systemic anomalies that are absent in typical ODCRCS patients. Therefore, the biochemical nature of the TBD variants is a key driver of the expanded clinical spectrum observed in these five newly identified cases.

Insights from Precision Animal Modeling

To validate the pathogenicity of the identified variants, researchers employed sophisticated animal modeling techniques, including a prime editing N1 screen in mouse embryos. This strategy allowed the team to observe the effects of the p.Glu66Lys variant in a heterozygous state, mimicking the human condition. Remarkably, the heterozygous mouse embryos displayed perinatal lethality, accompanied by soft palate clefts and significant skeletal abnormalities. This was a surprising contrast to traditional Axin2 null models, which are often viable and exhibit milder phenotypes. In addition to the mouse data, modeling of the variant in Drosophila (fruit fly) wings and eyes provided further clarity. The fly models demonstrated that the p.Glu66Lys variant could act as a gain-of-function or dominant negative allele depending on the specific tissue type. These results reinforce the idea that the TBD variants have unique biological properties that distinguish them from other AXIN2 mutations. Moreover, the success of the N1 screening strategy highlights a potent new method for resolving variants of uncertain significance. By utilizing these precision models, scientists can confirm the causal link between specific mutations and complex human phenotypes.

Clinical Implications for Pediatric and Genetic Practice

For clinicians in specialties such as pediatrics, genetics, and oncology, these findings have immediate practical implications. The discovery of AXIN2-related phenotypic expansion means that AXIN2 should no longer be viewed solely as a "dental and colon" gene. Instead, it must be integrated into differential diagnoses for children with unexplained global developmental delay and microcephaly. Furthermore, the presence of ectodermal dysplasia features, such as sparse hair or abnormal nails, should prompt a thorough genetic evaluation of the Wnt signaling pathway. Early identification of these variants is critical for providing appropriate multi-disciplinary care, which may include neurodevelopmental support, ophthalmologic monitoring, and long-term surveillance for colorectal cancer risk. Additionally, the study highlights the importance of de novo variants in congenital disorders, which often require parental testing to confirm the mode of inheritance. As genetic testing becomes more accessible in clinical settings, the ability to correlate specific domain-related variants with predictable clinical outcomes will become a cornerstone of personalized medicine. Therefore, staying informed about such phenotypic expansions is vital for improving diagnostic accuracy and patient outcomes in rare disease management.

The Future of Genomic Medicine and Variant Resolution

The successful resolution of the p.Glu66Lys variant using the N1 modeling strategy sets a new standard for functional genomics. As we identify more heterozygous variants associated with congenital anomalies, the need for rapid and accurate validation becomes paramount. This study demonstrates that even well-known genes can harbor surprises when variants occur in specific, understudied domains. Furthermore, the move toward precision modeling allows for a deeper understanding of the tissue-specific effects of Wnt signaling. In the future, these modeling techniques may lead to the development of targeted therapies that can modulate Wnt activity in a context-dependent manner. Consequently, the intersection of clinical observation and precision animal modeling will continue to drive the evolution of genomic medicine.

FAQ: Frequently Asked Questions

What clinical features distinguish this expanded AXIN2 phenotype from the classic Oligodontia-Colorectal Cancer Syndrome?

While the classic phenotype (ODCRCS) primarily involves severe tooth agenesis and an increased risk of colorectal cancer, the expanded AXIN2-related phenotypic expansion includes significant neurodevelopmental and systemic issues. Patients often present with microcephaly, global developmental delay, and ectodermal dysplasia. Furthermore, these individuals may exhibit diverse structural abnormalities affecting the limbs, eyes, and genitourinary system. This broader clinical spectrum highlights the critical need for comprehensive genetic screening in pediatric patients with multiple congenital anomalies.

How does the specific location of the variant within the tankyrase-binding domain impact AXIN2 function?

The tankyrase-binding domain (TBD) is essential for regulating AXIN2 protein stability through a process known as PARsylation. Variants such as p.Glu66Lys disrupt the binding between AXIN2 and tankyrase, which typically signals the protein for degradation. When this interaction is impaired, AXIN2 levels become dysregulated, leading to abnormal Wnt signaling. Interestingly, animal models suggest that these specific variants can produce either gain-of-function or dominant negative effects depending on the biological context of the cell.

Why is the N1 mouse modeling strategy considered a breakthrough for evaluating de novo heterozygous variants?

Traditionally, validating the pathogenicity of de novo heterozygous variants is difficult because many knockout mouse models do not fully replicate human disease states. The N1 modeling strategy, which utilizes prime editing in mouse embryos, allows researchers to observe the effects of specific human variants in a heterozygous state during development. In this study, it confirmed that the p.Glu66Lys variant is perinatal lethal in mice, providing robust functional evidence of pathogenicity that standard viable null models could not provide.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or as a substitute for the advice of a qualified healthcare professional. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Aceves-Ewing NM et al. Uncovering Phenotypic Expansion in AXIN2-Related Disorders through Precision Animal Modeling. Genet Med. 2026 Jul 09. doi: undefined. PMID: 42429102.

van de Moosdijk AAA et al. A novel Axin2 knock-in mouse model for visualization and lineage tracing of WNT/CTNNB1 responsive cells. Genesis. 2020;58(9):e23387.

Aceves-Ewing NM et al. Uncovering Phenotypic Expansion in AXIN2-Related Disorders through Precision Animal Modeling. medRxiv. 2025. doi: 10.1101/2025.03.01.25323214.